Market capitalization | JPY4.61t |
Enterprise Value | JPY4.59t |
P/E (TTM) P/E ratio | 38.64 |
EV/FCF (TTM) EV/FCF | 35.49 |
EV/Sales (TTM) EV/Sales | 4.65 |
P/S ratio (TTM) P/S ratio | 4.68 |
P/B ratio (TTM) P/B ratio | 3.51 |
Dividend yield | 0.84% |
Last dividend (FY25) | JPY26.00 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
16 Analysts have issued a Terumo forecast:
16 Analysts have issued a Terumo forecast:
Sep '24 |
+/-
%
|
||
Revenue | 986,674 986,674 |
15%
15%
|
|
Gross Profit | 527,942 527,942 |
20%
20%
|
|
EBITDA | 243,285 243,285 |
25%
25%
|
EBIT (Operating Income) EBIT | 161,480 161,480 |
32%
32%
|
Net Profit | 119,486 119,486 |
21%
21%
|
In millions JPY.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Terumo Corp. engages in the manufacturing and sale of medical products and equipment. It operates through the following segments: Cardiac and Vascular Company, General Hospital Company, and Blood Management Company. The Cardiac and Vascular Company segment offers services and treatments including cardiac and vascular surgery and interventional therapies performed inside blood vessels. The General Hospital Company segment provides infusion and closed anticancer drug infusion systems, measuring devices system with communication functions, diabetes management, adhesion barrier, and peritoneal dialysis. The Blood Management Company segment offers a combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction. The company was founded by Shibasaburo Kitasato on September 17, 1921 and is headquartered in Tokyo, Japan
Head office | Japan |
CEO | Hikaru Samejima |
Employees | 30,591 |
Founded | 1921 |
Website | www.terumo.co.jp |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.